A citation-based method for searching scientific literature

Dan Lu, Tong Lu, Mark Stroh, Richard A Graham, Priya Agarwal, Luna Musib, Chi-Chung Li, Bert L Lum, Amita Joshi. Cancer Chemother Pharmacol 2016
Times Cited: 35







List of co-cited articles
71 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.
Jeffrey R Sachs, Kapil Mayawala, Satvik Gadamsetty, Soonmo Peter Kang, Dinesh P de Alwis. Clin Cancer Res 2016
66
25

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
Pasi A Jänne, Geoffrey Kim, Alice T Shaw, Rajeshwari Sridhara, Richard Pazdur, Amy E McKee. Clin Cancer Res 2016
24
25

Optimizing dosing of oncology drugs.
L Minasian, O Rosen, D Auclair, A Rahman, R Pazdur, R L Schilsky. Clin Pharmacol Ther 2014
46
17

Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
K Venkatakrishnan, L E Friberg, D Ouellet, J T Mettetal, A Stein, I F Trocóniz, R Bruno, N Mehrotra, J Gobburu, D R Mould. Clin Pharmacol Ther 2015
69
14

Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
Julie M Bullock, Atiqur Rahman, Qi Liu. Clin Cancer Res 2016
26
15

Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.
C Liu, J Yu, H Li, J Liu, Y Xu, P Song, Q Liu, H Zhao, J Xu, V E Maher,[...]. Clin Pharmacol Ther 2017
87
11

Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Leonard V Sacks, Hala H Shamsuddin, Yuliya I Yasinskaya, Khaled Bouri, Michael L Lanthier, Rachel E Sherman. JAMA 2014
105
11

Determining the optimal dose in the development of anticancer agents.
Ron H J Mathijssen, Alex Sparreboom, Jaap Verweij. Nat Rev Clin Oncol 2014
101
11

Advancing Clinical Trials to Streamline Drug Development.
Susan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, Stuart Bailey, Patricia M LoRusso, Eric H Rubin. Clin Cancer Res 2015
23
13

Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.
K Venkatakrishnan, C Burgess, N Gupta, A Suri, T Takubo, X Zhou, D DeMuria, M Lehnert, K Takeyama, S Singhvi,[...]. Clin Transl Sci 2016
19
15

Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
J Wang, P Song, S Schrieber, Q Liu, Q Xu, G Blumenthal, L Amiri Kordestani, P Cortazar, A Ibrahim, R Justice,[...]. Clin Pharmacol Ther 2014
45
8

Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
Nicholas S Downing, Nilay D Shah, Jenerius A Aminawung, Alison M Pease, Jean-David Zeitoun, Harlan M Krumholz, Joseph S Ross. JAMA 2017
154
8

Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu, Walter Bordogna, Bogdana Balas, Francois Mercier. Cancer Chemother Pharmacol 2018
15
20


Rare cancer trial design: lessons from FDA approvals.
Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur. Clin Cancer Res 2012
39
5


Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Amita Patnaik, S Peter Kang, Drew Rasco, Kyriakos P Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino,[...]. Clin Cancer Res 2015
451
5

Failures in Phase III: Causes and Consequences.
Bostjan Seruga, Alberto Ocana, Eitan Amir, Ian F Tannock. Clin Cancer Res 2015
49
5

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.
Paul Morgan, Piet H Van Der Graaf, John Arrowsmith, Doug E Feltner, Kira S Drummond, Craig D Wegner, Steve D A Street. Drug Discov Today 2012
397
5

Advances in cancer therapeutics.
A Sparreboom, J Verweij. Clin Pharmacol Ther 2009
26
7


Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Marc R Theoret, Lee H Pai-Scherf, Meredith K Chuk, Tatiana M Prowell, Sanjeeve Balasubramaniam, Tamy Kim, Geoffrey Kim, Paul G Kluetz, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2015
26
7

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.
Lorea Bueno, Dinesh P de Alwis, Celine Pitou, Jonathan Yingling, Michael Lahn, Sophie Glatt, Iñaki F Trocóniz. Eur J Cancer 2008
156
5

Exposure response--getting the dose right.
José Pinheiro, Stephen Duffull. Pharm Stat 2009
8
25

A time to event tutorial for pharmacometricians.
Nick Holford. CPT Pharmacometrics Syst Pharmacol 2013
54
5

Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
Roelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, Frank G A Jansman. Lancet Oncol 2014
148
5

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Raymond Perez, Robin E Norris, John Nemunaitis, Huyuan Yang, Mark G Qian, Gerald Falchook, Richard Labotka,[...]. Br J Clin Pharmacol 2016
28
7

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Neeraj Gupta, Michael J Hanley, R Donald Harvey, Ashraf Badros, Brea Lipe, Vishal Kukreti, Jesus Berdeja, Huyuan Yang, Ai-Min Hui, Mark Qian,[...]. Br J Haematol 2016
34
5


Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson,[...]. N Engl J Med 2016
618
5

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Paul G Richardson, Philippe Moreau, Jacob P Laubach, Neeraj Gupta, Ai-Min Hui, Kenneth C Anderson, Jesús F San Miguel, Shaji Kumar. Future Oncol 2015
19
10

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Neeraj Gupta, Yeow Tee Goh, Chang-Ki Min, Jae Hoon Lee, Kihyun Kim, Raymond S M Wong, Chor Sang Chim, Michael J Hanley, Huyuan Yang, Karthik Venkatakrishnan,[...]. J Hematol Oncol 2015
32
6

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Paul G Richardson, Rachid Baz, Michael Wang, Andrzej J Jakubowiak, Jacob P Laubach, R Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu,[...]. Blood 2014
162
5

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Neeraj Gupta, Paul M Diderichsen, Michael J Hanley, Deborah Berg, Helgi van de Velde, R Donald Harvey, Karthik Venkatakrishnan. Clin Pharmacokinet 2017
29
6

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Shaji K Kumar, William I Bensinger, Todd M Zimmerman, Craig B Reeder, James R Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu,[...]. Blood 2014
155
5

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Neeraj Gupta, Yuan Zhao, Ai-Min Hui, Dixie-Lee Esseltine, Karthik Venkatakrishnan. Br J Clin Pharmacol 2015
46
5

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Mehdi Hamadani, A Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio,[...]. Lancet Oncol 2014
191
5

Importance of food effects for oral oncology drugs.
Mark J Ratain. Clin Adv Hematol Oncol 2012
4
50

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.
Lei Nie, Eric H Rubin, Nitin Mehrotra, José Pinheiro, Laura L Fernandes, Amit Roy, Stuart Bailey, Dinesh P de Alwis. Clin Cancer Res 2016
37
5


Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.
B Darpo, C Benson, C Dota, G Ferber, C Garnett, C L Green, V Jarugula, L Johannesen, J Keirns, K Krudys,[...]. Clin Pharmacol Ther 2015
118
5

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.
Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, Jeffrey S Weber. Clin Cancer Res 2013
107
5

Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Shang-Chiung Chen, Angelica Quartino, Daniel Polhamus, Matthew Riggs, Jonathan French, Xin Wang, Shweta Vadhavkar, Melanie Smitt, Silke Hoersch, Alexander Strasak,[...]. Br J Clin Pharmacol 2017
12
16

PBPK modeling and simulation in drug research and development.
Xiaomei Zhuang, Chuang Lu. Acta Pharm Sin B 2016
132
5

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Neeraj Gupta, Yeamin Huh, Matthew M Hutmacher, Sean Ottinger, Ai-Min Hui, Karthik Venkatakrishnan. Cancer Chemother Pharmacol 2015
19
10

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
Hongshan Li, Jingyu Yu, Chao Liu, Jiang Liu, Sriram Subramaniam, Hong Zhao, Gideon M Blumenthal, David C Turner, Claire Li, Malidi Ahamadi,[...]. J Pharmacokinet Pharmacodyn 2017
67
5

The combination of exposure-response and case-control analyses in regulatory decision making.
Jun Yang, Hong Zhao, Christine Garnett, Atiqur Rahman, Jogarao V Gobburu, William Pierce, Genevieve Schechter, Jeffery Summers, Patricia Keegan, Brian Booth,[...]. J Clin Pharmacol 2013
61
5

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
180
5


Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Neeraj Gupta, Huyuan Yang, Michael J Hanley, Steven Zhang, Rachael Liu, Shaji Kumar, Paul G Richardson, Tomas Skacel, Karthik Venkatakrishnan. Target Oncol 2017
16
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.